Iradimed Co Stock Current Valuation
| IRMD Stock | USD 44.70 0.85 1.94% |
Valuation analysis of Iradimed helps investors to measure Iradimed's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to 51.10. The current year's Enterprise Value Multiple is expected to grow to 51.10. Fundamental drivers impacting Iradimed's valuation include:
Price Book 7.2985 | Enterprise Value 511.6 M | Enterprise Value Ebitda 22.7656 | Price Sales 7.9757 | Forward PE 24.0964 |
Overvalued
Today
Please note that Iradimed's price fluctuation is very steady at this time. Calculation of the real value of Iradimed is based on 3 months time horizon. Increasing Iradimed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Iradimed Co is useful when determining the fair value of the Iradimed stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Iradimed. Since Iradimed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iradimed Stock. However, Iradimed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 44.7 | Real 36.71 | Target 58.33 | Hype 43.85 | Naive 44.78 |
The real value of Iradimed Stock, also known as its intrinsic value, is the underlying worth of Iradimed Company, which is reflected in its stock price. It is based on Iradimed's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Iradimed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Iradimed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Iradimed Co helps investors to forecast how Iradimed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iradimed more accurately as focusing exclusively on Iradimed's fundamentals will not take into account other important factors: Iradimed Co Company Current Valuation Analysis
Iradimed's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Iradimed Current Valuation | 511.64 M |
Most of Iradimed's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iradimed Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Iradimed Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Iradimed is extremely important. It helps to project a fair market value of Iradimed Stock properly, considering its historical fundamentals such as Current Valuation. Since Iradimed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iradimed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iradimed's interrelated accounts and indicators.
Click cells to compare fundamentals
Iradimed Current Valuation Historical Pattern
Today, most investors in Iradimed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iradimed's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Iradimed current valuation as a starting point in their analysis.
Iradimed Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Iradimed Co has a Current Valuation of 511.64 M. This is 96.44% lower than that of the Health Care Equipment & Supplies sector and 95.88% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.92% higher than that of the company.
Iradimed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iradimed's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iradimed could also be used in its relative valuation, which is a method of valuing Iradimed by comparing valuation metrics of similar companies.Iradimed is currently under evaluation in current valuation category among related companies.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 263.8M | 276.4M | 570.5M | 355.4M | 598.3M | 628.2M | |
| Enterprise Value | 223.3M | 229.1M | 511.0M | 299.6M | 550.5M | 578.1M |
Iradimed Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 511.64 M | ||||
| Shares Outstanding | 12.64 M | ||||
| Shares Owned By Insiders | 37.03 % | ||||
| Shares Owned By Institutions | 55.05 % | ||||
| Number Of Shares Shorted | 104.88 K | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 7.30 X | ||||
| Price To Sales | 7.98 X | ||||
| Revenue | 65.56 M | ||||
| Gross Profit | 41.28 M | ||||
| EBITDA | 20.04 M | ||||
| Net Income | 17.19 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 2.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | 13.47 M | ||||
| Short Ratio | 2.35 X | ||||
| Earnings Per Share | 1.35 X | ||||
| Price To Earnings To Growth | 4.46 X | ||||
| Target Price | 62.5 | ||||
| Number Of Employees | 148 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 557.99 M | ||||
| Total Asset | 92.16 M | ||||
| Retained Earnings | 43.26 M | ||||
| Working Capital | 59.67 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 92.16 M | ||||
| Last Dividend Paid | 0.15 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Iradimed Piotroski F Score and Iradimed Altman Z Score analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.185 | Dividend Share 0.15 | Earnings Share 1.35 | Revenue Per Share 5.363 | Quarterly Revenue Growth 0.137 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.